Find Reports

Select Report Type

Reimbursement Review

Displaying 226 - 250 of 1258

Please scroll or swipe to the right to view the full content.

Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Ultomiris	ravulizumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Paroxysmal nocturnal hemoglobinuria	Reimburse with clinical criteria and/or conditions	Complete	Jul 22, 2021	Feb 11, 2022	SR0700-000
Bijuva	estradiol and progesterone	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Vasomotor symptoms associated with menopause	Reimburse with clinical criteria and/or conditions	Complete	Jun 30, 2021	Feb 10, 2022	SR0697-000
Waymade-Trientine	trientine hydrochloride	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Wilson's Disease	Reimburse with clinical criteria and/or conditions	Complete	Jul 21, 2021	Feb 8, 2022	SR0696-000
Leqvio	inclisiran	Response to the Procedural Review Panel’s Memorandum Report on the Procedural R…Memorandum report to CADTH Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Primary hypercholesterolemia	Do not reimburse	Complete	Mar 17, 2021	Feb 7, 2022	SR0681-000
Sarclisa	isatuximab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Multiple myeloma	Reimburse with clinical criteria and/or conditions	Complete	Jul 15, 2021	Jan 28, 2022	PC0256-000
Darzalex	daratumumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Light chain (AL) amyloidosis	Reimburse with clinical criteria and/or conditions	Complete	Jul 15, 2021	Jan 28, 2022	PC0257-000
Trodelvy	sacituzumab govitecan	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions	Locally advanced or metastatic triple-negative breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Jun 30, 2021	Jan 27, 2022	PC0254-000
Piqray	alpelisib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Advanced or Metastatic Breast Cancer	Do not reimburse	Complete	Apr 21, 2021	Jan 26, 2022	PC0247-000
Opdivo	nivolumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report	Esophageal or gastroesophageal junction cancer	Reimburse with clinical criteria and/or conditions	Complete	Jul 7, 2021	Jan 26, 2022	PC0253-000
Perjeta	pertuzumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Early stage breast cancer	Do not reimburse	Complete	Apr 14, 2021	Jan 25, 2022	PC0241-000
Dojolvi	triheptanoin	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Long-chain fatty acid oxidation disorders	Reimburse with clinical criteria and/or conditions	Complete	Mar 31, 2021	Jan 21, 2022	SR0684-000
Increlex	mecasermin	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Severe primary insulin-like growth factor-1 deficiency	Reimburse with clinical criteria and/or conditions	Complete	Jun 14, 2021	Jan 21, 2022	SR0692-000
Imvexxy	estradiol	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Dyspareunia	Reimburse with clinical criteria and/or conditions	Complete	Jun 23, 2021	Jan 20, 2022	SR0694-000
Tagrisso	osimertinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Non-small cell lung cancer	Reimburse with clinical criteria and/or conditions	Complete	Mar 24, 2021	Jan 10, 2022	PC0246-000
Padcev	enfortumab vedotin	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Locally advanced or metastatic urothelial carcinoma	Reimburse with clinical criteria and/or conditions	Complete	Jun 23, 2021	Jan 6, 2022	PC0251-000
Brukinsa	zanubrutinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Waldenström’s macroglobulinemia	Reimburse with clinical criteria and/or conditions	Complete	May 21, 2021	Dec 21, 2021	PC0248-000
Keytruda	pembrolizumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Esophageal carcinoma, gastroesophageal junction adenocarcinoma	Reimburse with clinical criteria and/or conditions	Complete	May 26, 2021	Dec 20, 2021	PC0250-000
Emgality	galcanezumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Prevention of migraine	Reimburse with clinical criteria and/or conditions	Complete	Jun 3, 2021	Dec 15, 2021	SR0693-000
Opsynvi	macitentan and tadalafil	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Pulmonary arterial hypertension	Reimburse with clinical criteria and/or conditions	Complete	May 20, 2021	Dec 14, 2021	SR0690-000
Reblozyl	luspatercept	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Myelodysplastic syndromes-associated anemia	Reimburse with clinical criteria and/or conditions	Complete	Jan 28, 2021	Dec 7, 2021	SR0670-000
Ledaga	chlormethine hydrochloride	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	T-cell lymphoma	Do not reimburse	Complete	Dec 21, 2020	Nov 24, 2021	PC0242-000
Tukysa	tucatinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Advanced or Metastatic Breast Cancer	Reimburse with clinical criteria and/or conditions	Complete	Mar 26, 2021	Nov 17, 2021	PC0243-000
Abecma	idecabtagene vicleucel	Recommendation and Reasons Clinical, Pharmacoeconomic, and Ethics combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Multiple myeloma	Do not reimburse	Complete	Dec 16, 2020	Nov 12, 2021	PG0240-000
MAR-Trientine	Trientine Hydrochloride	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Wilson's Disease	Reimburse with clinical criteria and/or conditions	Complete	Apr 19, 2021	Nov 11, 2021	SR0680-000
Evenity	romosozumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Osteoporosis, postmenopausal women	Reimburse with clinical criteria and/or conditions	Complete	Feb 1, 2021	Nov 11, 2021	SR0676-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 226 - 250 of 589

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Internet-Delivered Cognitive Behavioural Therapy in the Treatment of Chronic Non-Cancer Pain	Internet-Delivered Cognitive Behavioural Therapy in the Treatment of Chronic No…Project Protocol	Oct 3, 2022	Optimal Use	Completed	HT0037-000 - OP0550-000
Cannabis for Opioid Use Disorder	Cannabis for Opioid Use Disorder	Oct 3, 2022	Rapid Review	Completed	RC1454-000
Real Time Continuous Glucose Monitoring for People Living with Type 2 Diabetes	Real Time Continuous Glucose Monitoring for People Living with Type 2 Diabetes	Sep 28, 2022	Rapid Review	Completed	RC1443-000
Mepivacaine Versus Bupivacaine for Patients Undergoing Total Joint Arthroplasty	Mepivacaine Versus Bupivacaine for Patients Undergoing Total Joint Arthroplasty	Sep 22, 2022	Rapid Review	Completed	RC1453-000
Therapeutic Support for Pressure Injuries	Therapeutic Support for Pressure Injuries	Sep 15, 2022	Rapid Review	Completed	RC1450-000
Airway Pressure Release Ventilation for Acute Respiratory Distress Syndrome: An Update	Airway Pressure Release Ventilation for Acute Respiratory Distress Syndrome: An…	Sep 15, 2022	Rapid Review	Completed	RC1451-000
Antiviral Prophylaxis With Tenofovir for Patients With History of Hepatitis B Receiving Oncology Drug Treatment	Antiviral Prophylaxis With Tenofovir for Patients With History of Hepatitis B R…	Sep 9, 2022	Rapid Review	Completed	RC1448-000
RWE Learning Project Non-Oncology: Ocaliva		Sep 8, 2022	Technology Review	In Progress	HC0046-000
Considerations for the use of COVID-19 Rapid Tests	Considerations for the use of COVID-19 Rapid Tests	Sep 2, 2022	Environmental Scan	Completed	ES0364-000
Utilization of Glucagon-Like Peptide-1 Receptor Agonists	Utilization of Glucagon-Like Peptide-1 Receptor Agonists	Sep 1, 2022	Technology Review	Completed	HC0042-000
Real-Time Continuous Glucose Monitoring for People Living With Type 1 Diabetes	Real-Time Continuous Glucose Monitoring for People Living With Type 1 Diabetes	Aug 22, 2022	Rapid Review	Completed	RC1442-000
Health Technology Assessment Recommendations and Managed Entry Agreements Related to Optimizing the Treatment for Pediatric Spinal Muscular Atrophy		Aug 17, 2022	Environmental Scan	In Progress	ES0368-000
Virtual Care Use in Primary Care or Specialty Care Settings	Virtual Care Use in Primary Care or Specialty Care Settings In-Brief Guidelines for use of virtual care in primary care or specialty care s…	Aug 17, 2022	Rapid Review	Completed	RC1444-000
Concurrent or Sequential Administration of Drugs for COVID-19 and Influenza	Concurrent or Sequential Administration of Drugs for COVID-19 and Influenza	Aug 15, 2022	Rapid Review	Completed	RC1446-000
Liposuction for Lipedema: A 2022 Update	Liposuction for Lipedema: 2022 Update	Aug 12, 2022	Rapid Review	Completed	RC1447-000
Mesalamine for the Treatment of Crohn Disease	Mesalamine for the Treatment of Crohn’s Disease	Aug 10, 2022	Rapid Review	Completed	RC1445-000
Post-COVID-19 Condition: A summary of existing guidelines	Post-COVID-19 Condition: A summary of existing guidelines	Aug 4, 2022	Technology Review	Complete	HC0037-000
Portable Bone Imaging Devices for Screening and Diagnosing Osteoporosis	Portable Bone Imaging Devices for Screening and Diagnosing Osteoporosis	Aug 2, 2022	Rapid Review	Completed	RC1438-000
Models of Care for People Re-Entering the Community After Incarceration	Models of Care for People Re-Entering the Community After Incarceration	Aug 2, 2022	Technology Review	Completed	HC0039-000
Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma	Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Trea…	Aug 2, 2022	Rapid Review	Completed	RC1441-000
Interventions for the treatment of obstructive sleep apnea: economic update		Jul 29, 2022	Technology Review	In Progress	HE0038-000
Guanfacine for Autism Spectrum Disorder, Attention-Deficit/Hyperactivity Disorder, and/or Oppositional Defiance Disorder	Guanfacine for Autism Spectrum Disorder, Attention-Deficit/Hyperactivity Disord…	Jul 27, 2022	Rapid Review	Completed	RC1440-000
Multiple Prosthetic Sockets for Lower Limb Amputations	Multiple Prosthetic Sockets for Lower Limb Amputations	Jul 21, 2022	Rapid Review	Completed	RC1439-000
Improving Access to Primary Care in Canada	Improving Access to Primary Care in Canada	Jul 19, 2022	Environmental Scan	Completed	ES0363-000
Diacetylmorphine for Adults With Opioid Dependence	Diacetylmorphine for Adults With Opioid Dependence	Jul 18, 2022	Rapid Review	Completed	RC1437-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 111 of 111

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 226 - 250 of 2093

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
datopotamab deruxtecan			Oct 18, 2024	Reimbursement Review		Cancelled	PC0384-000
Re-treatment With Immune Checkpoint Inhibitors: Utilization Analysis			Oct 16, 2024	Health Technology Review	Technology Review	In Progress	HC0093-000
bimekizumab		Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Oct 10, 2024	Reimbursement Review		Complete	SR0809-000
leniolisib			Oct 10, 2024	Reimbursement Review		Suspended	SR0792-000
metreleptin		Recommendations and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Oct 10, 2024	Reimbursement Review		Complete	SR0784-000
The Effectiveness of PCSK9 Inhibitors in Familial Hypercholesterolemia			Oct 10, 2024	Health Technology Review	Observational Study	Active	OS0011-000
The Cost-Effectiveness and Budget Impact of Remdesivir for Outpatient Treatment of COVID-19			Oct 10, 2024	Health Technology Review	Technology Review	In Progress	HE0049-000
Prostate Cancer		Final Report	Oct 9, 2024	Reimbursement Review	Provisional Funding Algorithm	Active	PH0050-000
The Cost-Effectiveness and Budget Impact of Tocilizumab for COVID-19			Oct 8, 2024	Health Technology Review	Technology Review	Active	HE0051-000
The Cost-Effectiveness and Budget Impact of Remdesivir for Inpatient Treatment of COVID-19			Oct 8, 2024	Health Technology Review	Technology Review	Active	HE0050-000
osilodrostat			Oct 8, 2024	Reimbursement Review		Suspended	SR0804-000
amivantamab			Oct 4, 2024	Reimbursement Review		Pending	PC0393-000
Bilateral Opportunistic Salpingectomy to Reduce the Incidence of Ovarian Cancer		Bilateral Opportunistic Salpingectomy to Reduce the Incidence of Ovarian Cancer	Oct 4, 2024	Health Technology Review	Summary with Critical Appraisal	Completed	RC1550-000
insulin icodec		Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Oct 3, 2024	Reimbursement Review		Complete	SR0790-000
Lenvatinib for the Treatment of Hepatocellular Carcinoma After Liver Transplant		Lenvatinib for the Treatment of Hepatocellular Carcinoma After Liver Transplant	Oct 2, 2024	Health Technology Review	Rapid Review	Completed	RC1553-000
Switching Calcitonin Gene–Related Peptide Inhibitors for Migraine Prophylaxis		Switching Calcitonin Gene–Related Peptide Inhibitors for Migraine Prophylaxis	Sep 27, 2024	Health Technology Review	Peer-reviewed Summary with Critical Appraisal	Completed	RD0071-000
etranacogene dezaparvovec		Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Sep 26, 2024	Reimbursement Review		Complete	SG0805-000
nivolumab		Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Sep 26, 2024	Reimbursement Review		Complete	PC0339-000
Cost-Effectiveness of Conjugate Pneumococcal Vaccines in At-Risk Adults Aged 18 to 64 Years		Cost-Effectiveness of Conjugate Pneumococcal Vaccines in At-Risk Adults Aged 18…	Sep 26, 2024	Health Technology Review	Technology Review	Completed	HE0054-000
Pharmaceutical Reviews Update — Issue 51			Sep 26, 2024	Reimbursement Review	Pharmaceutical Review Update
avatrombopag		Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Sep 25, 2024	Reimbursement Review		Complete	SR0721-000
Short-Cycle Autoclave Sterilization of Instruments in Same-Day Ophthalmic Surgeries		Short-Cycle Autoclave Sterilization of Instruments in Same-Day Ophthalmic Surgeries	Sep 25, 2024	Health Technology Review	Rapid Review	Completed	RC1547-000
maralixibat		Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	Sep 20, 2024	Reimbursement Review		Complete	SR0780-000
Continuously Diffused Therapy for Wound Healing	To inform decisions about continuously diffused oxygen (CDO) therapy for wound healing, we identified and summarized literature comparing the clinical effectiveness and cost-effectiveness of CDO therapy versus conventional wound care.	Continuously Diffused Therapy for Wound Healing	Sep 20, 2024	Health Technology Review	Rapid Review	Completed	RC1548-000
The Cost-Effectiveness and Budget Impact of Nirmatrelvir-Ritonavir for COVID-19			Sep 19, 2024	Health Technology Review	Technology Review	Active	HE0048-000